Skip to main content

Feminizing Procedures

Feminizing gender-affirming procedures span the breast / chest, genitalia, face, neck, and voice, each with distinct techniques, outcomes, and considerations. This page is organized by procedure category. For overview principles, see GAS Overview; for revisions, see Revision & Salvage GAS.

Breast Augmentation​

Breast augmentation is the most commonly performed feminizing GAS procedure, with 74% of transfeminine respondents in the U.S. Transgender Survey having undergone or desiring it.1 ACOG recommends waiting at least 6 months after initiating feminizing hormone therapy before surgery, though some experts suggest 2–3 years to maximize hormonal breast development.1

Key technical and outcome considerations:

  • Implant placement — subglandular or subpectoral, depending on body habitus and patient preference. Transfeminine patients have wider base widths, longer sternal-notch-to-nipple distances, and require larger implants (median 500 mL vs 350 mL in cisgender women), often necessitating routine inframammary fold lowering.123
  • Complications — a meta-analysis of 1,864 transfeminine patients found pooled rates of capsular contracture 3.6%, hematoma / seroma 0.6%, and implant asymmetry / malposition 3.9%. Compared with cisgender women, transfeminine patients had statistically higher rates of hematoma and implant malposition.4
  • Satisfaction — 100% satisfaction with cosmetic results in one series, with all patients reporting improved psychosocial well-being. In a large Dutch cohort, 80% were satisfied with results, though approximately one-third reported health complaints attributed to implants.25
  • Reoperation rate — approximately 5% due to complications, with capsular contracture being the most common indication.6

Vaginoplasty​

Vaginoplasty is the most frequently performed feminizing genital surgery, with 87% of transfeminine respondents desiring it.1 The goal is to create an aesthetic and functional vulva and vaginal canal enabling receptive intercourse, erogenous clitoral sensation, and a downward-directed urine stream.7

Surgical Techniques​

  • Penile inversion vaginoplasty (PIV) — the gold standard. Penile skin is inverted to line the neovaginal canal, scrotal skin creates the labia, and the glans penis is used to construct a sensate clitoris via the dorsal neurovascular pedicle technique. Preoperative scrotal electrolysis is recommended to prevent intravaginal hair growth.18
  • Peritoneal pull-through vaginoplasty — increasingly used when penile skin is insufficient (e.g., prior circumcision, puberty blocker use). Laparoscopically harvested peritoneal flaps are combined with inverted penile skin, producing a self-lubricating neovagina. In a series of 52 patients, mean vaginal depth was 14.7 cm, with 96% satisfaction and a low complication rate (13.5%).9
  • Intestinal (sigmoid) vaginoplasty — most commonly used after failed primary vaginoplasty; provides spontaneous mucus secretion but carries higher morbidity.8
  • Minimal-depth (vulvoplasty) — for patients who do not desire vaginal penetration; creates external female genitalia without a vaginal canal. Detailed in Non-Binary & Nullification.7

Complications​

Complication rates have been documented as high as 70%, though most are minor and do not alter long-term outcomes.7 In the largest U.S. cohort (117 patients), the most common complications were granulation tissue (26%), intravaginal scarring (20%), and prolonged pain (20%).10 Major complications include rectovaginal fistula, rectal injury, and urethral / introital stenosis.7 Vaginal stenosis is the most frequent complication across all techniques and is the primary consequence of inadequate dilation.1112

Outcomes and Satisfaction​

Despite moderate complication risk, 94% of patients reported feeling positively about their genitals and would undergo the operation again; 71% reported resolution of gender dysphoria.10 A 2025 prospective study demonstrated significant postoperative improvement in depression (PHQ-9), anxiety (GAD-7), gender congruence, body image, and sexual function scores, with pain returning to baseline by 12 months.13

Postoperative Care​

  • Dilation — lifelong commitment required; up to 3 times daily initially, gradually decreasing. Permanent vaginal stenosis results from non-adherence.114
  • Vaginal hygiene — the neovagina is skin-lined and colonized by a combination of skin flora and vaginal species. Discharge or odor is commonly due to dead skin, sebum, or retained lubricant; douching with dilute vinegar / betadine is typically adequate. Persistent odor may be treated with a 5-day course of vaginal metronidazole.14
  • Prostate screening — performed vaginally, not rectally, as the prostate lies anterior to the constructed vagina.14
  • STI risk — genitourinary infections can be treated using standard guidelines for cisgender patients, though risk may differ depending on tissue type used.14

Facial Feminization Surgery (FFS)​

FFS is a group of craniomaxillofacial procedures that modify masculine facial features toward feminine proportions. It is often prioritized by patients because the face is the most publicly visible feature and directly affects social perception and safety.8 In a needs assessment, 65% of transfeminine respondents desired at least one FFS procedure.15

Common Procedures by Facial Third161718​

  • Upper third (49% of all FFS procedures) — forehead recontouring / frontal bone reduction (most common single procedure at 34.6%), brow lift, hairline advancement.
  • Middle third — rhinoplasty (12.8%), cheek augmentation, blepharoplasty.
  • Lower third — chin remodeling / genioplasty (12.2%), mandible / jaw reduction, lip lift, vermilion reconstruction.

Patients self-identify their brows (54.5%), jaws (33.3%), and chins (30.3%) as the most masculine aspects of their faces.19

Outcomes​

A prospective multicenter study of 66 patients demonstrated that the median Facial Feminization Outcome Score increased from 47.2 preoperatively to 80.6 at ≥ 6 months (p < 0.001), with significant improvements in mental health, social function, and quality of life.161920

Chondrolaryngoplasty (Tracheal Shave)​

This procedure reduces the anterior projection of the thyroid cartilage ("Adam's apple") and is frequently combined with other FFS procedures.2122 Desired by 45% of transfeminine individuals in one survey.15

  • Techniques — transcervical, transoral, or endoscopic-assisted approaches. Laryngoscopic-assisted techniques allow intraoperative vocal cord visualization to minimize injury risk.21
  • Complications — minimal; scarring and patient dissatisfaction with amount of cartilage removed are most common. Rare complications include dysphonia, hematoma, and laryngospasm. In a series of 32 patients, only one experienced temporary hoarseness that resolved within 6 weeks.2122

Voice Feminization​

Voice is the source of the strongest dysphoria among transfeminine individuals (median 7/10).15 Options include voice therapy, surgery, or a combined approach.

  • Voice therapy (VT) — first-line; raises speaking fundamental frequency (SF0) with significant effect size (g = 0.86) and improved quality of life.23
  • Wendler glottoplasty — the preferred and most reliable surgical intervention; creates an anterior glottic web to shorten the vibrating length of the vocal folds. Effect size for SF0 improvement g = 1.21.2324
  • Feminization laryngoplasty — reduces the overall size of the larynx and pharynx, raising both fundamental and resonant frequencies. Largest effect size (g = 3.05) but less generalizable data.2325
  • Combined approach — integration of voice therapy and surgery is significantly more effective than therapy alone.24

Trade-offs include potential impact on vocal projection and risk of long-term dysphonia; postsurgical voice rehabilitation improves outcomes.24

Perioperative Hormone Management​

A key clinical question is whether to continue or discontinue estrogen perioperatively due to VTE concerns. See also the Gender-Affirming Hormone Therapy hub.

  • Current evidence supports continuation — in a study of 407 transfeminine vaginoplasty cases, no VTE events occurred among those who continued estrogen, while the single VTE event occurred in the group that suspended estrogen. A retrospective study of 183 patients using an individualized algorithm found that 75% continued estradiol perioperatively with a VTE rate of only 0.05% and no difference in complications between groups.2627
  • WPATH SOC 8 now recommends continuation of estrogen perioperatively to avoid estrogen withdrawal symptoms (gender dysphoria exacerbation, vasomotor symptoms, suicidal ideation).28
  • Practice variation persists — a survey of 51 GAS surgeons found that the majority do not stop HRT before surgery, but 43% still discontinue it for feminizing bottom surgery, with wide variation in discontinuation schedules.29
  • Transdermal estradiol is not associated with increased VTE risk in postmenopausal literature and may be preferred in higher-risk patients.30
  • DVT prophylaxis is generally provided to all patients in the first week after surgery regardless of estrogen status.29

Eligibility and Timing Summary​

ProcedureHormone Therapy Before SurgeryMental Health LettersMinimum Age
Breast augmentation≥ 6 months (some suggest 2–3 years)118
Vaginoplasty≥ 12 months218
Orchiectomy≥ 12 months218
Facial feminization surgeryVariable (no strict minimum)1Case-by-case
Voice surgeryNo strict requirementCase-by-caseCase-by-case

Sources: ACOG 2021,1 Coon 2020,2 Endocrine Society 2017,31 WPATH SOC 8.32

Footnotes​

  1. Cronin B, Stockdale CK. "Health Care for Transgender and Gender Diverse Individuals." American College of Obstetricians and Gynecologists, 2021. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  2. Coon D, Lee E, Fischer B, Darrach H, Landford WN. "Breast Augmentation in the Transfemale Patient: Comprehensive Principles for Planning and Obtaining Ideal Results." Plast Reconstr Surg. 2020;145(6):1343–1353. doi:10.1097/PRS.0000000000006819 ↩ ↩2 ↩3

  3. Torres Perez-Iglesias CA, Heyman A, Koh DJ, et al. "Technical and Clinical Differences Between Transgender and Cisgender Females Undergoing Breast Augmentation." Ann Plast Surg. 2023;91(5):534–539. doi:10.1097/SAP.0000000000003706 ↩

  4. Liu C, Shahid M, Yu Q, et al. "Complications Following Breast Augmentation in Transfeminine Individuals: A Systematic Review and Meta-Analysis." Plast Reconstr Surg. 2024;153(6):1240–1251. doi:10.1097/PRS.0000000000010691 ↩

  5. de Blok CJM, Staphorsius AS, Wiepjes CM, et al. "Frequency, Determinants, and Satisfaction of Breast Augmentation in Trans Women Receiving Hormone Treatment." J Sex Med. 2020;17(2):342–348. doi:10.1016/j.jsxm.2019.10.021 ↩

  6. Schoffer AK, Bittner AK, Hess J, Kimmig R, Hoffmann O. "Complications and Satisfaction in Transwomen Receiving Breast Augmentation: Short- and Long-Term Outcomes." Arch Gynecol Obstet. 2022;305(6):1517–1524. doi:10.1007/s00404-022-06603-3 ↩

  7. Morrison SD, Claes K, Morris MP, et al. "Principles and Outcomes of Gender-Affirming Vaginoplasty." Nat Rev Urol. 2023;20(5):308–322. doi:10.1038/s41585-022-00705-y ↩ ↩2 ↩3 ↩4

  8. Wylie K, Knudson G, Khan SI, et al. "Serving Transgender People: Clinical Care Considerations and Service Delivery Models in Transgender Health." Lancet. 2016;388(10042):401–411. doi:10.1016/S0140-6736(16)00682-6 ↩ ↩2 ↩3

  9. Castanon CDG, Matic S, Bizic M, et al. "Laparoscopy Assisted Peritoneal Pull-Through Vaginoplasty in Transgender Women." Urology. 2022;166:301–302. doi:10.1016/j.urology.2022.05.001 ↩

  10. Massie JP, Morrison SD, Van Maasdam J, Satterwhite T. "Predictors of Patient Satisfaction and Postoperative Complications in Penile Inversion Vaginoplasty." Plast Reconstr Surg. 2018;141(6):911e–921e. doi:10.1097/PRS.0000000000004427 ↩ ↩2

  11. Horbach SE, Bouman MB, Smit JM, et al. "Outcome of Vaginoplasty in Male-to-Female Transgenders: A Systematic Review of Surgical Techniques." J Sex Med. 2015;12(6):1499–1512. doi:10.1111/jsm.12868 ↩

  12. Bishop MD, Morgan-Daniel J, Alappattu MJ. "Pain and Dysfunction Reported After Gender-Affirming Surgery: A Scoping Review." Phys Ther. 2023;103(7):pzad045. doi:10.1093/ptj/pzad045 ↩

  13. Haley C, Roblee CV, Blasdel G, et al. "Gender-Affirming Vaginoplasty Improves Quality of Life in Transfeminine Individuals: A Single-Center Prospective Study." Ann Surg. 2025. doi:10.1097/SLA.0000000000006988 ↩

  14. Jackson Q, Yedlinsky NT, Gray M. "Lifelong Care of Patients After Gender-Affirming Surgery." Am Fam Physician. 2024;109(6):560–565. ↩ ↩2 ↩3 ↩4

  15. Ziltzer RS, Lett E, Su-Genyk P, Chambers T, Moayer R. "Needs Assessment of Gender-Affirming Face, Neck, and Voice Procedures and the Role of Gender Dysphoria." Otolaryngol Head Neck Surg. 2023;169(4):906–916. doi:10.1002/ohn.329 ↩ ↩2 ↩3

  16. Siringo NV, Berman ZP, Boczar D, et al. "Techniques and Trends of Facial Feminization Surgery: A Systematic Review and Representative Case Report." Ann Plast Surg. 2022;88(6):704–711. doi:10.1097/SAP.0000000000002952 ↩ ↩2

  17. Ellis M, Choe J, Barnett SL, Chen K, Bradley JP. "Facial Feminization: Perioperative Care and Surgical Approaches." Plast Reconstr Surg. 2024;153(1):181e–193e. doi:10.1097/PRS.0000000000010886 ↩

  18. Azizi A, Sun A, Cheng LH, Hassan B, Liang F. "Facial Gender-Affirming Surgery: Upper and Middle Face Feminization." Clin Plast Surg. 2025;52(4):435–452. doi:10.1016/j.cps.2025.07.002 ↩

  19. Morrison SD, Capitán-Cañadas F, Sánchez-García A, et al. "Prospective Quality-of-Life Outcomes After Facial Feminization Surgery: An International Multicenter Study." Plast Reconstr Surg. 2020;145(6):1499–1509. doi:10.1097/PRS.0000000000006837 ↩ ↩2

  20. Morrison SD, Vyas KS, Motakef S, et al. "Facial Feminization: Systematic Review of the Literature." Plast Reconstr Surg. 2016;137(6):1759–1770. doi:10.1097/PRS.0000000000002171 ↩

  21. James AJ, Assi PE, Torres-Guzman RA, et al. "Optimizing Safety and Aesthetics in Facial Feminization: Laryngoscopic-Assisted Chondrolaryngoplasty (2019–2023)." J Craniofac Surg. 2024. doi:10.1097/SCS.0000000000010398 ↩ ↩2 ↩3

  22. Goslawski A, Spiegel JH. "Chondrolaryngoplasty." J Craniofac Surg. 2025;36(2):738–743. doi:10.1097/SCS.0000000000011134 ↩ ↩2

  23. Lanham K, Melnick BA, O'Connor MJ, et al. "Efficacy and Patient Satisfaction in Voice Feminization Procedures: A Systematic Review and Meta-Analysis." Otolaryngol Head Neck Surg. 2025;172(5):1521–1538. doi:10.1002/ohn.1173 ↩ ↩2 ↩3

  24. McBrinn S, Antoni C, Al Yaghchi C. "Current Approaches to Gender-Affirming Vocal Care." Curr Opin Otolaryngol Head Neck Surg. 2024;32(3):143–150. doi:10.1097/MOO.0000000000000967 ↩ ↩2 ↩3

  25. Thomas JP. "Feminization Laryngoplasty — A Comprehensive Approach to Reducing the Size of the Larynx and Pharynx." Otolaryngol Clin North Am. 2022;55(4):739–748. doi:10.1016/j.otc.2022.05.002 ↩

  26. Kozato A, Fox GWC, Yong PC, et al. "No Venous Thromboembolism Increase Among Transgender Female Patients Remaining on Estrogen for Gender-Affirming Surgery." J Clin Endocrinol Metab. 2021;106(4):e1586–e1590. doi:10.1210/clinem/dgaa966 ↩

  27. Herndon J, Gupta N, Davidge-Pitts C, et al. "Genital Surgery Outcomes Using an Individualized Algorithm for Hormone Management in Transfeminine Individuals." J Clin Endocrinol Metab. 2024;109(11):2774–2783. doi:10.1210/clinem/dgae269 ↩

  28. Maharaj SK, Yu A, Singh A, Khanijow K. "Transforming Culture: Postoperative Venous Thromboembolism Prophylaxis in a Transgender Patient on Estrogen." J Gen Intern Med. 2025. doi:10.1007/s11606-025-09668-3 ↩

  29. Hung YC, Assi PE, Park BC, et al. "Patterns of Perioperative Hormone Therapy for Gender-Affirming Surgery." Ann Plast Surg. 2024;92(4):442–446. doi:10.1097/SAP.0000000000003820 ↩ ↩2

  30. Nolan BJ, Cheung AS. "Estradiol Therapy in the Perioperative Period: Implications for Transgender People Undergoing Feminizing Hormone Therapy." Yale J Biol Med. 2020;93(4):539–548. ↩

  31. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. "Endocrine Treatment of Gender-Dysphoric / Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2017;102(11):3869–3903. doi:10.1210/jc.2017-01658 ↩

  32. Dakkak M, Kriegel DL II, Tauches K. "Caring for Transgender and Gender-Diverse People: Guidelines From WPATH." Am Fam Physician. 2023;108(6):626–629. ↩